There is also evolving evidence that PD-1-expressing tumor-infiltrating lymphocytes (TILs) and high PD-1 messenger RNA expression could be important predictors of PD-1/PD-L1 antibody responsiveness [22,23]. This evidence concerns the gene PDCD1 and neoplasm.